Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the completion of the transaction, the director directly owned 351,875 shares of the company’s stock, valued at $88,014,493.75. The trade was a 1.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Trading Up 0.8%

Shares of Jazz Pharmaceuticals stock traded up $1.86 during mid-day trading on Wednesday, hitting $245.57. 1,155,945 shares of the stock were exchanged, compared to its average volume of 969,018. Jazz Pharmaceuticals PLC has a twelve month low of $123.88 and a twelve month high of $266.38. The stock has a market capitalization of $15.94 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 0.23 and a beta of 0.36. The company has a 50-day simple moving average of $248.07 and a 200 day simple moving average of $219.83. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business’s quarterly revenue was up 15.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($8.25) EPS. Research analysts forecast that Jazz Pharmaceuticals PLC will post 21.5 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $283.00 to $322.00 and gave the stock an “overweight” rating in a report on Wednesday, August 26th. Truist Financial upped their target price on Jazz Pharmaceuticals from $264.00 to $281.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Stifel Nicolaus set a $275.00 price target on Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Finally, Needham & Company LLC lifted their price target on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average price target of $285.44.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Triumph Capital Management boosted its holdings in Jazz Pharmaceuticals by 2.0% in the second quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock valued at $626,000 after acquiring an additional 52 shares during the last quarter. Bessemer Group Inc. grew its position in Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after acquiring an additional 73 shares during the period. UMB Bank n.a. increased its stake in Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 81 shares during the last quarter. Pinnacle Associates Ltd. increased its stake in Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after acquiring an additional 83 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 4.4% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after purchasing an additional 85 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.